ImmuCell Corporation — 2017 Form 10-K
Reporting period: Fiscal year ended December 31, 2017. ImmuCell develops and sells animal-health products for dairy and beef cattle. Its established First Defense product line prevents calf scours; its principal development program is an FDA-regulated Nisin treatment for subclinical mastitis in lactating cows.
Financial performance and position
| Metric | 2017 | 2016 | Change |
|---|---|---|---|
| Product sales | $10.43 million | $9.54 million | +9% |
| Gross margin | $5.22 million; 50% of sales | $5.42 million; 57% of sales | Margin down 7 percentage points |
| Operating income (loss) | ($243,000) | $890,000 | Turned to loss |
| Net income (loss) | ($168,000); ($0.03) per share | $508,000; $0.12 per share | Turned to loss |
| Cash from operations | $1.18 million | ($222,000) | Improved |
| Capital expenditures | $17.76 million | $3.59 million | Primarily Nisin facility investment |
| Cash, cash equivalents and short-term investments | $3.80 million | $10.62 million | Down $6.83 million |
| Bank debt outstanding | $9.09 million | $3.01 million | Up substantially |
At year-end, working capital was $5.44 million, total assets were $34.30 million, and stockholders’ equity was $23.59 million. Cash less bank debt was approximately negative $5.29 million. The company reported compliance with debt covenants and said available cash, product margins, and bank financing should fund operations and requirements for at least 12 months from filing.
Material changes and operating developments
- Sales rose 9%, with domestic sales up 4% and international sales up 43%. First Defense represented 94% of product sales, versus 93% in 2016; two distributors accounted for 64% of annual sales.
- Gross margin fell to 50% from 57%. Management cited lower-than-normal biological yields, costly initial Tri-Shield production, batches that failed quality standards, higher input and labor costs, and cGMP compliance costs.
- Product development spending increased 64% to $2.05 million, mainly for the Nisin mastitis product; sales and marketing costs increased 3% to $1.89 million.
- Operating cash flow improved to $1.18 million, but heavy investment drove investing cash outflow to $12.27 million. The company spent $17.76 million on capital expenditures and raised equity and debt financing.
- Construction of the approximately $21 million Nisin manufacturing facility was completed in the fourth quarter. Depreciation began on the building; equipment installation and qualification were expected to continue into 2018. Property, plant and equipment, net, increased to $26.07 million from $9.85 million.
- Tri-Shield First Defense, with USDA-approved claims against three major scours pathogens, launched in late 2017. The company discontinued its topical wipes line during the first quarter.
Outlook, risks and unusual items
- Nisin development: Management projected FDA approval in late 2019 to early 2020, subject to regulatory review and requests. It expected to submit the Human Food Safety section in early 2018 and phased Chemistry, Manufacturing and Controls submissions beginning in mid-2018. Three commercial-scale registration batches, FDA review, and successful inspections remained necessary. The product had not yet been approved for sale.
- Production and demand: First-quarter 2018 demand exceeded available inventory for Tri-Shield and legacy First Defense formats. Management anticipated approximately $303,000 of Tri-Shield and $652,000 of other First Defense backlog at March 31, 2018, and targeted inventory aligned with expected demand by the third quarter of 2018. It identified biological yield and availability of the rotavirus vaccine used for source cows as constraints.
- Capacity and financial burden: Management expected higher depreciation, estimating approximately $2.0 million for 2018, and warned this could contribute to operating losses. It estimated 2018 interest expense of approximately $441,000 if remaining loan proceeds were drawn, using an assumed 4.5% rate. Much of the debt bears variable interest rates; $6.14 million was not covered by interest-rate swaps at year-end.
- Commercial targets, not formal guidance: Management’s stated objective was to double current product sales to approximately $20 million through First Defense growth and a successful mastitis launch; its longer-term goal was $30 million in sales within five years after the mastitis product launches. These are targets, not reported results or guaranteed forecasts.
- Key risks: Reliance on First Defense; concentration in two distributors and in dairy and beef markets; competition from larger animal-health companies; uncertainty around yields, production scale-up, regulatory approval, market adoption, and premium pricing; and potential supply disruption from contractors. The Norbrook manufacturing agreement could trigger a $100,000 termination fee if FDA approval was not achieved by the end of 2019. Milk-culture interference, market-size uncertainty, and variable-rate debt are additional risks.
- Tax and other items: The 2017 tax benefit was $270,000, including an estimated $71,000 benefit from remeasuring deferred taxes after the U.S. corporate tax rate reduction. The company said it was continuing to assess the tax-law impact. A $150,000 Baylor license milestone and $5,000 royalty related to Tri-Shield approval were accrued at year-end and paid in January 2018. No material pending legal proceedings were reported.
- The independent auditor issued an unqualified opinion on the financial statements. Management assessed disclosure controls and internal control over financial reporting as effective; the auditor did not provide an attestation on internal control.
Important facts for investors to verify
- Whether First Defense production yields recover and backlogs are cleared without lost sales or lasting customer impact.
- Progress and actual timing of Nisin commercial-scale batches, FDA submissions, inspections, approval, and launch; related spending, depreciation, and debt-service effects.
- Whether gross margin stabilizes near management’s approximately 50% objective and whether operating cash flow can support investment and debt repayments.
- Distributor concentration, customer receivable exposure, variable interest rates, covenant compliance, and remaining funding needs.
- Whether Tri-Shield and eventual Nisin sales meet market, pricing, and production assumptions; stated sales targets are uncertain and should not be treated as guidance.